Apellis Pharmaceuticals, Inc. has been on a fast-growth trajectory driven by the launch of Syfovre (pegcetacoplan injection), the first drug approved by the US Food and Drug Administration for geographic atrophy, secondary to age-related macular degeneration (AMD). The early launch performance has been outpacing investor expectations, but the emergence of events of retinal vasculitis in the real-world setting threatens to curb near-term growth.
Apellis’ Syfovre Sales Overshadowed By Safety Concerns
Second quarter sales of the new geographic atrophy drug exceeded expectations, but the company confirmed seven events of retinal vasculitis in patients treated with Syfovre in the real world.
More from Sensory
• By
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
• By
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
• By
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
• By
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.
More from Therapy Areas
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.